US FDA extends review of Bayer's menopause relief drug

Bayer announced the US FDA extended its review of the experimental menopause drug elinzanetant (Lynkuet) by up to 90 days, without raising concerns regarding its general approvability. This non-hormonal treatment is critical for Bayer's pharmaceutical growth strategy, targeting over $1 billion in peak annual sales to offset declining Xarelto revenue. The extension delays a key market launch for a drug already approved in the UK and Canada, impacting Bayer's near-term revenue projections and competitive positioning against Astellas' approved Veozah in the US market.

Analysis

The U.S. FDA's decision to extend its review of Bayer's elinzanetant by up to 90 days introduces a meaningful delay to a key asset in the company's pharmaceutical pipeline. This non-hormonal menopause treatment, with expected peak annual sales of at least $1 billion, is crucial for offsetting declining revenue from the blockbuster drug Xarelto. The postponement of the planned 2024 launch cedes additional market-building time to Astellas' competing drug, Veozah, which is already approved in the U.S. for the same indication. However, the impact is mitigated by Bayer's statement that the FDA did not raise concerns regarding the drug's general approvability. This, coupled with recent approvals for elinzanetant in the United Kingdom and Canada, suggests the delay is likely procedural and that eventual approval remains probable, albeit on a revised timeline.

Key Decisions for Investors

• Investors should adjust near-term revenue models for Bayer's pharmaceutical division to account for the delayed launch of elinzanetant, pushing expected US sales contributions into late 2024 or early 2025.
• It is critical to monitor the market penetration and sales growth of Astellas' competing drug, Veozah, during this 90-day period to assess the competitive landscape elinzanetant will face upon potential approval.
• Given that the FDA did not raise fundamental approvability concerns, the final decision remains the key catalyst, and long-term holders should watch for the resolution of this procedural delay.